[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584035":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":25,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A (RT)","EXPERIMENTAL","Period 1: Reference Drug (AD-2284), Period 2: Test Drug (AD-228B)",[13,14],"Drug: AD-228B","Drug: AD-2284",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B (TR)","Period 1: Test Drug (AD-228B), Period 2: Reference Drug (AD-2284)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-228B","AD-228B, 1Tab., Per Oral",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-2284","AD-2284, 1Tab., Per Oral",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"JeongEun Park","CONTACT","+82-31-891-6989","parkje@addpharma.co.kr",[37],{"facility":38,"status":39,"city":40,"state":25,"zip":25,"country":41,"countryCode":25,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"H Plus Yangji Hospital","RECRUITING","Seoul","South Korea",{"type":43,"coordinates":44},"Point",[45,46],126.9784,37.566,{"lat":46,"lon":45},[49],{"name":50,"role":33,"phone":51,"phoneExt":25,"email":52},"SeungHyun Kang","+82-70-4665-9490","juspa@newyjh.com",{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100584035","phase-1-a-study-to-compare-pk-characteristics-and-safety-profiles-between-ad-228b-and-ad-2284-100584035",false,"NCT06884098","A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years",{"count":66,"type":67},60,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.",[73],"Primary Hypercholesterolaemia","2025-03-18",{"date":76,"type":77},"2025-03-20","ACTUAL",{"date":79,"type":77},"2025-03-10",{"date":81,"type":67},"2025-04",{"name":5,"class":6},1]